Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
NCT ID: NCT05158062
Last Updated: 2022-04-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
35 participants
INTERVENTIONAL
2022-04-20
2024-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
NCT05170594
A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
NCT02608684
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
NCT00407563
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
NCT04575961
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02853318
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pembrolizumab and bevacizumab with PBC followed by pembrolizumab, bevacizumab and olaparib
Participants will continue treatment period up to 6 cycles and enter maintenance period after treatment period. Study treatment will be continued until progressive disease (PD) based on RECIST 1.1, death, unacceptable toxicity, or participant withdrawal from the study.
pembrolizumab
pembrolizumab 200 mg every three weeks (Q3W)
olaparib
olaparib 300 mg twice daily (BID) during maintenance period
bevacizumab
bevacizumab 15 mg/kg Q3W
carboplatin
carboplatin AUC=5 or 6 Q3W during treatment period
paclitaxel
paclitaxel 175 mg/m2 Q3W during treatment period
docetaxel
docetaxel 60 \~ 70 mg/m2 Q3W during treatment period
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pembrolizumab
pembrolizumab 200 mg every three weeks (Q3W)
olaparib
olaparib 300 mg twice daily (BID) during maintenance period
bevacizumab
bevacizumab 15 mg/kg Q3W
carboplatin
carboplatin AUC=5 or 6 Q3W during treatment period
paclitaxel
paclitaxel 175 mg/m2 Q3W during treatment period
docetaxel
docetaxel 60 \~ 70 mg/m2 Q3W during treatment period
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participant has received only one regimen of PBC (3 cycles or more) as prior therapy with clinical CR (determined by negative clinical examination and a normal CA-125 level).
3. Participant has documentation of progressive disease at least 6 months from completion of PBC (platinum-sensitive).
4. Participant with measurable disease based on RECIST 1.1 at screening
5. Participant is able to provide a core or excisional biopsy of a tumor for testing of PD-L1 status, etc.
6. Participant with Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1 at the screening
7. Participant has a life expectancy of at least 12 weeks as determined by the investigators.
8. Participant has adequate organ function.
Exclusion Criteria
2. Participant has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
3. Participant has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to the first dose of study drug.
4. Participant has received prior radiotherapy within 2 weeks of the first dose of study drug.
5. Participant has received major surgery within 4 weeks prior to the first dose of study drug.
6. Participant has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.
7. Participant is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study drug.
8. Participant has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
9. Participant has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
10. Participant has known active CNS metastases and/or carcinomatous meningitis.
11. Participant has severe hypersensitivity (≥Grade 3) to the study treatment and/or any of its excipients.
12. Participant has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
13. Participant has a history of (non-infectious) pneumonitis/interstitial lung disease that required treatment with steroids or has current pneumonitis/interstitial lung disease.
14. Participant has an active infection requiring systemic therapy.
15. Participant has a known history of Human Immunodeficiency Virus (HIV) infection.
16. Participant has a known history of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection.
17. Participant has received colony-stimulating factors (granulocyte colony stimulating factor \[G-CSF\], granulocyte macrophage colony-stimulating factor \[GM-CSF\] or recombinant erythropoietin) within 2 weeks prior to the first dose of study drug.
18. Participant has clinically serious cardiovascular/cerebrovascular diseases (eg, cerebrovascular accident/stroke \[less than 6 month prior to enrollment\], myocardial infarction \[less than 6 month prior to enrollment\], uncontrolled and potentially reversible cardiac conditions \[unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation \>500 msec, electrolyte disturbances, hypertension defined as systolic \>150 mmHg or diastolic \>90 mmHg etc.\] or participant has congenital long QT syndrome).
19. Participant has known abdominal fistula, gastrointestinal fistula or gastrointestinal perforation and/or higher risks of bleeding.
20. Participant has either myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or has features suggestive of MDS/AML.
21. Participant is currently receiving either strong (eg, itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate (eg, ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued prior to the first dose of study drug.
22. Participant is currently receiving either strong (eg, phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine, and St John's Wort) or moderate (eg, bosentan, efavirenz, modafinil) inducers of CYP3A4 that cannot be discontinued prior to the first dose of study drug.
23. Participant is either unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (eg, gastrectomy, partial bowel obstruction, malabsorption).
24. Participant has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
25. Participant is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 210 days after the last dose of study treatment.
26. Participant has had an allogenic tissue/solid organ transplant.
27. Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the investigators.
20 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kosei Hasegawa, MD, PhD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kosei Hasegawa, MD, PhD
Professor and Director, Department of Gynecologic Oncology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kosei Hasegawa, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Saitama Medical University International Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saitama Medical Uiversity International Medical Center
Hidaka, Saitama, Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SaINT-ov02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.